Deutsch English Français

Contact

EP2827872

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2827872

EP2827872 - COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH OTHER ANTI-TUMOR COMPOUNDS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 23.10.2015 Database last updated on 08.06.2024
Most recent event Tooltip	23.10.2015	Application deemed to be withdrawn	published on 25.11.2015 [2015/48]
Applicant(s)	For all designated states Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE
	[2015/05]
Inventor(s)	01 / BLADT, Friedhelm Werderstrasse 36 69120 Heidelberg / DE
	02 / FRIESE-HAMIM, Manja Stockhaussenstrasse 1 64546 Moerfelden-Walldorf / DE
	[2015/05]
Application number, filing date	13705919.2	21.02.2013
	WO2013EP00495
Priority number, date	EP20120001847	19.03.2012 Original published format: EP 12001847
	[2015/05]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2013139423
	Date:	26.09.2013
	Language:	EN
	[2013/39]
	Type:	A1 Application with search report
	No.:	EP2827872
	Date:	28.01.2015
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 26.09.2013 takes the place of the publication of the European patent application.
	[2015/05]
Search report(s)	International search report - published on:	EP	26.09.2013
Classification	IPC:	A61K31/506, A61K39/395, A61P35/00, A61K31/517	[2015/05]
	CPC:	A61K31/506 (EP,US); A61K31/517 (EP,US); A61K39/3955 (US); A61K39/39558 (EP,US); A61P35/00 (EP); A61P35/02 (EP); (+) A61P43/00 (EP); C07K16/22 (EP,US); C07K16/2863 (EP,US); A61K2039/505 (US) (-)
	C-Set:	A61K31/506, A61K2300/00 (EP,US); A61K31/517, A61K2300/00 (EP); A61K39/39558, A61K2300/00 (US,EP)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/05]
Title	German:	KOMBINATION AUS EINEM 6-OXO-1,6-DIHYDROPYRIDAZINDERIVAT MIT WIRKUNG GEGEN KREBS UND ANDEREN ANTITUMORVERBINDUNGEN	[2015/05]
	English:	COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH OTHER ANTI-TUMOR COMPOUNDS	[2015/05]
	French:	COMBINAISON D'UN DÉRIVÉ DE 6-OXO-1,6-DIHYDRO-PYRIDAZINE AYANT UNE ACTIVITÉ ANTICANCÉREUSE AVEC D'AUTRES COMPOSÉS ANTI-TUMORAUX	[2015/05]
Entry into regional phase	22.07.2014	National basic fee paid
	22.07.2014	Designation fee(s) paid
	22.07.2014	Examination fee paid
Examination procedure	22.07.2014	Examination requested [2015/05]
	09.05.2015	Application deemed to be withdrawn, date of legal effect [2015/48]
	23.06.2015	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time [2015/48]
Fees paid	Renewal fee
	11.02.2015	Renewal fee patent year 03
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[XYI]WO2010078897 (MERCK PATENT GMBH [DE], et al) [X] 1-4,6-8,10-14 * p. 1, l. 7-11; p. 10, l. 4-7; p. 14, l. 24 to p. 16, l. 11; p. 19, l. 20 to p. 21, l. 23; p. 26, box "Tyrosine kinase inhibitors"; p. 36, l. 11-16; claims 21-24 * [Y] 1,2,5,9,11-15 [I] 15;
		[Y] - TENG L S ET AL, "Clinical Applications of VEGF-Trap (Aflibercept) in Cancer Treatment", JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, ELSEVIER (SINGAPORE) PTE LTD, HONG KONG BRANCH, HK, vol. 73, no. 9, ISSN 1726-4901, (20100901), pages 449 - 456, (20100901), XP027338632 [Y] 1,2,5,9,11-15 * whole document, particularly chapter "Preclinical and clinical benefits of incorporating VEGF-Trap into anticancer treatment strategies" *
		[A] - LAACK E ET AL, "Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 69, no. 3, ISSN 0169-5002, (20100901), pages 259 - 264, (20100619), XP027172036 [A] 1-3,7,11-15 * the whole document *
		[A] - ON BEHALF OF THE SATURN INVESTIGATORS ET AL, "Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 11, no. 6, doi:10.1016/S1470-2045(10)70112-1, ISSN 1470-2045, (20100601), pages 521 - 529, (20100601), XP027068157 [A] 1-3,7,11-15 * the whole document * DOI: http://dx.doi.org/10.1016/S1470-2045(10)70112-1
		[A] - ETTINGER ET AL, "Emerging profile of cetuximab in non-small cell lung cancer", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 68, no. 3, ISSN 0169-5002, (20100601), pages 332 - 337, (20090926), XP027037714 [A] 1,2,4,8,11-15 * the whole document *
		[A] - ON BEHALF OF THE FLEX STUDY TEAM ET AL, "Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial", THE LANCET, LANCET LIMITED. LONDON, GB, vol. 373, no. 9674, doi:10.1016/S0140-6736(09)60569-9, ISSN 0140-6736, (20090502), pages 1525 - 1531, (20090430), XP026088699 [A] 1,2,4,8,11-15 * the whole document * DOI: http://dx.doi.org/10.1016/S0140-6736(09)60569-9
		[A] - CRINO L ET AL, "Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 11, no. 8, doi:10.1016/S1470-2045(10)70151-0, ISSN 1470-2045, (20100801), pages 733 - 740, (20100801), XP027598755 [A] 1,2,6,10-15 * the whole document * DOI: http://dx.doi.org/10.1016/S1470-2045(10)70151-0
		[A] - TOBIAS ENGEL AYER BOTREL ET AL, "Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 74, no. 1, doi:10.1016/J.LUNGCAN.2011.01.028, ISSN 0169-5002, (20110130), pages 89 - 97, (20110205), XP028288125 [A] 1,2,6,10-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.lungcan.2011.01.028
	by applicant	WO2009006959
		WO2009007074
		- PHARMACEUTICAL RESEARCH, (1986), vol. 3, no. 6, page 318

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p